Top 7 Treatment Advances Transforming Thoracic Outlet Syndrome Care According to a newly published market research report by 24LifeSciences, global thoracic outlet syndrome treatment market is valued at USD 1.52 billion in 2026 and is projected to reach USD 2.27 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.1% during the forecast period. Thoracic Outlet Syndrome (TOS) is a complex clinical condition caused by the compression of neurovascular structuresthe brachial plexus, subclavian artery, and subclavian veinas they pass through the thoracic outlet, the narrow space between the collarbone and first rib. This compression manifests in three primary types: neurogenic TOS (most prevalent), venous TOS, and arterial TOS, each requiring distinct diagnostic and therapeutic strategies. The increasing clinical recognition of its varied symptomatology, from pain and numbness to vascular complications, underscores its growing significance in musculoskeletal and vascular medicine. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9226/thoracic-outlet-syndrome-treatment-market